Novartis | NVS - Ebitda





Ebitda Veränderung Datum
AbbVie USD 5.37B 1.85B 2025-12
Amgen USD 5.14B 775M 2025-12
AstraZeneca USD 5.67B 1.29B 2026-03
Bausch Health Companies USD 837M 94M 2026-03
Biogen USD 649.7M 76.5M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Canopy Growth CAD -137M 134.13M 2026-03
Corcept Therapeutics USD 4.2M 6.5M 2025-12
Drreddys Laboratories INR 8.63B 12.96B 2026-03
Eli Lilly USD 12.14B 4.26B 2025-12
Gilead Sciences USD 3.02B 1.01B 2025-12
GlaxoSmithKline GBP 2.77B 1.65B 2026-03
Glaxosmithkline GBP 2.77B 1.98B 2026-03
J&J USD 8.27B 1.08B 2026-03
Merck USD 6.3B 2.09B 2025-12
Novartis USD 6.48B 1.19B 2026-06
Novartis USD 5.41B 431M 2026-03
Pacira USD 40.24M 1.53M 2026-03
Perrigo USD 141.6M 1.34B 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Phibro Animal Health USD 68.1M 6.2M 2025-12
Prestige Brands USD 90.82M 3.99M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Sanofi EUR 3.31B 3.65B 2026-03
Sanofi EUR 2.72B 2.94B 2026-03
Supernus Pharmaceuticals USD 29.23M 19.27M 2026-03
Zoetis USD 939M 101M 2025-12